Document is current
Any future updates will be listed below
-
Authors
Horner, David https://orcid.org/0000-0002-0200-4561
Vinding, Rebecca
Wang, Tingting https://orcid.org/0000-0002-9100-3447
Ali, Mina
Lovric, Mario https://orcid.org/0000-0002-3541-9624
Prince, Nicole https://orcid.org/0000-0002-8506-1122
Lasky-Su, Jessica
Bønnelykke, Klaus https://orcid.org/0000-0003-2003-1018
Stokholm, Jakob https://orcid.org/0000-0003-4989-9769
Chawes, Bo https://orcid.org/0000-0001-6846-6243
Rasmussen, Morten Arendt https://orcid.org/0000-0001-7431-5206
-
Funding
Funding for this research was provided by:
Strategiske Forskningsråd (0603-00280B)
Lundbeckfonden (R16-A1694)
Lundbeckfonden (R269-2017-5)
EC | Horizon 2020 Framework Programme (946228)
Novo Nordisk Fonden (NNF21OC0068517)
Foundation for the National Institutes of Health (R01HL123915, R01HL155742, R01HL141826 and K01HL153941;amp;#x200B;;amp;#x200B;)
- License Information
-
More Information
Article History
Received: 18 October 2024
Accepted: 27 November 2025
First Online: 17 December 2025
Competing interests
: J.L.-S. is a scientific advisor for Precion Inc and a consultant to Tru Diagnostic, Inc. Remaining authors (D.H., R.V., T.W., M.A., M.L., N.P., J.L.S., K.B., J.S., B.C., and M.R.) declare no potential, perceived, or real conflict of interest regarding the content of this manuscript. The funding agencies did not have any role in the design and conduct of the study; collection, management, and interpretation of the data; or preparation, review, or approval of the manuscript. No pharmaceutical company was involved in the study.
